IRVINE, Calif., Feb. 29 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products and accessories used in angina-relieving procedures, today announced that it will delay its earnings release and investor conference call for the fourth quarter and full year ended December 31, 2007. The earnings release and investor conference call was previously scheduled for Tuesday, March 4, 2008.
The Company noted that the delay is due to logistical issues and is unrelated to any significant changes in the Company's financial condition, results of operations or in the effectiveness of the Company's internal controls. The Company will issue a subsequent announcement regarding the new date and time of its earnings release and conference call within the next week.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.
For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com/ or the direct to patient website at http://www.heartofnewlife.com/.
Cardiogenesis Corporation, +1-949-420-1800
http://www.cardiogenesis.com/
